Innovating Works

MERCURNA BV

Desconocido
ORGESTRA: Organoid technologies for disease modeling, drug discovery and development for rare diseases MERCURNA BV participó en un HORIZON EUROPE: HORIZON-MSCA-2022-DN-01 The vast majority of rare diseases are characterized by genetic origin, often severe in pathology and with limited or no treatment options....
2023-07-11 - 2027-12-31 | Financiado
NANEMIAR: Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia by messenger RNA MERCURNA BV participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Messenger RNA (mRNA) has recently proven itself as a prophylactic modality that can be rapidly developed and employed with high efficacy and...
2023-03-15 - 2026-09-30 | Financiado
INSIGHT EU: INSIGHT FOR EYESIGHT Novel mRNA medicines for eye disease MERCURNA BV tramitó un H2020: H2020-INNOSUP-2018-2020 Proper eyesight is essential for nearly all aspects of our life. Yet, over 4 million people suffer from reduced eyesight or blindness worldw...
2019-08-09 - 2021-02-27 | Financiado
NanoMed-CKD: Feasibility of mCura1 A kidney targeted nanomedicine that promotes self healing of Chronic Kidney D... MERCURNA BV tramitó un H2020: H2020-EIC-SMEInst-2018-2020 Chronic Kidney Disease (CKD) is a little-known disease, but does affect 10-13% of the population in Europe and constitutes the 9th cause of...
2018-11-15 - 2019-05-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.